Bernstein analyst Lee Hambright maintains Medtronic (NYSE:MDT) with a Outperform and lowers the price target from $100 to $99.
Bernstein lowered Medtronic (NYSE:MDT) price target from $100 to $99 Read Post »
Truist Securities Adjusts Price Target on Medtronic (NYSE:MDT) to $90 From $93, Maintains Hold Rating.
Truist Securities Adjusts Price Target on Medtronic (NYSE:MDT) to $90 From $93 Read Post »
RBC Capital analyst Shagun Singh reiterates Medtronic (NYSE:MDT) with a Sector Perform and maintains $89 price target.
RBC Capital maintained Medtronic (NYSE:MDT) $89 price target Read Post »
Barclays analyst Steve Valiquette maintains CVS Health (NYSE:CVS) with a Overweight and lowers the price target from $100 to $90.
Barclays lowered CVS Health (NYSE:CVS) price target from $100 to $90 Read Post »
Goldman Sachs analyst Nathan Rice maintains CVS Health (NYSE:CVS) with a Buy and lowers the price target from $100 to $88.
Goldman Sachs lowered CVS Health (NYSE:CVS) price target from $100 to $88 Read Post »
Raymond James analyst John Ransom maintains CVS Health (NYSE:CVS) with a Outperform and lowers the price target from $110 to $90.
Raymond James lowered CVS Health (NYSE:CVS) price target from $110 to $90 Read Post »
RBC Capital analyst Ben Hendrix reiterates CVS Health (NYSE:CVS) with a Outperform and maintains $102 price target.
RBC Capital maintained CVS Health (NYSE:CVS) $102 price target Read Post »
Piper Sandler analyst Jessica Tassan initiates coverage on CVS Health (NYSE:CVS) with a Overweight rating and announces Price Target of $85.
Piper Sandler announced CVS Health (NYSE:CVS) Price Target of $85 Read Post »
TD Cowen analyst Steve Scala maintains Eli Lilly (NYSE:LLY) with a Outperform and raises the price target from $430 to $500.
TD Cowen raised Eli Lilly (NYSE:LLY) price target from $430 to $500 Read Post »
Oppenheimer Adjusts Biogen (NASDAQ:BIIB) Price Target to $350 From $325, Maintains Outperform Rating.
Oppenheimer Adjusts Biogen (NASDAQ:BIIB) Price Target to $350 From $325 Read Post »
Argus Research analyst Jasper Hellweg maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $320 to $350.
Argus Research raised Biogen (NASDAQ:BIIB) price target from $320 to $350 Read Post »
Wedbush analyst Laura Chico reiterates Biogen (NASDAQ:BIIB) with a Neutral and maintains $263 price target.
Wedbush maintained Biogen (NASDAQ:BIIB) $263 price target Read Post »